>> Was this in the trial design? At the very least Bavi+ chemo should be compared to a clean chemo trial like the opdivo control arm.
Yes, if you didn't know before you should have. All oncology trials allow patients to take whatever available to them after progression, it is called subsequent therapies. There was no clean chemo arm in Opdivo control arm: over 50% patients on chemo arm went on having subsequent therapies, only 42% on Opdivo arm went on having subsequent therapies. See details here:
In SUNRISE trial, there was no reason only chemo arm patients who progressed went on having Opdivo/Keytruda as subsequent therapies, bavituximab arm patients could too. Some people speculated bavituximab arm patients not eligible to enroll PD1/PDL1 trials, it's nonsense. SUNRISE trial was double blinded, patients wouldn't know which arm they were on, no way affecting bavituximab arm patients differently from placebo arm patients if they wanted to enroll other trials after progression.
Market Data 
Markets 
AI
